An interventional study of adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate in Immunoclassification and Psoriasis, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-12.
Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one is the 31st largest by planned enrollment, is one of 3 that started in 2023, is one of 5 with no phase, and was the 41st registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
Sohag University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,042 studies on the registry; 499 are open to participants now.
Second Affiliated Hospital, School of Medicine, Zhejiang University has 6 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Through the combination of clinical manifestations and omics, the investigators aim to explore the skin cell atlas in different stages of psoriasis lesions, establish a clinical classification standard for psoriasis, and guide the precise treatment of psoriasis.
Psoriasis is a heterogeneous condition that can affect skin and other structures. Over the past decade, considerable advances have been made both in our understanding of the pathogenesis of psoriasis and in the revolutionized immunotherapy of its diverse manifestations. Psoriasis heterogeneity and its cutaneous microenvironment is the leading cause of resistance in patients.
Novel approaches, including single-cell RNA sequencing technology and CyTOF, are proposed as methodological solutions. By their combination with immunotherapy, we can specifically evaluate the mechanism of psoriasis in the face of immunotherapy agents at the single-cell resolution by detecting the transcriptional activity of cytokines, immune checkpoints, screening neoantigens with high transcription levels, identifying rare cells, and assisting the dissection of the critical immune-metabolic pathways in this complex disease. We aim to improve short-term and long-term precision treatment strategies for patients with psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1.18 to 75 years of age 2.Moderate to severe chronic psoriasis, BSA≥3% 3.Duration of psoriasis≥6 months 4.Patients must be candidate for systemic therapy 5. must be obtained 6.For female, ß-hCG test is negative and is accepted
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
Biological: adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
Drug pages: AdalimumabStudies of AdalimumabAdalimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · SecukinumabStudies of SecukinumabSecukinumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IxekizumabStudies of IxekizumabIxekizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GuselkumabStudies of GuselkumabGuselkumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · JAK inhibitorsStudies of JAK inhibitorsJAK inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MethotrexateStudies of MethotrexateMethotrexate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Psoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
Differences in the number of immune cells (dendritic cells, macrophages) in the lesional skin, non-lesional skin of psoriasis patients and healthy skin.
The intensity of specific cell subsets will be assessed by flow cytometry in psoriasis patients and healthy controls.
Time frame: 16 months
Molecular analysis of psoriasis lesional skin by single-cell RNA sequencing.
To analyze the intensity of cytokines or chemokines, such as IL-17, IL-23, TNF in the dermis and epidermis of psoriasis patients
Time frame: 16 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Dec 2027, 59 months after the start.
Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 59 months is above that.
Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adalimumab · Secukinumab · Ixekizumab · Guselkumab · JAK inhibitors · Methotrexate
Second Affiliated Hospital, School of Medicine, Zhejiang University →